L. Moise, A. Harris, D. Hanlon, A. Ball
SeromYx Systems, Massachusetts, United States
Keywords: biodefense, immunity, antibody, vaccine, immunotherapeutic
SeromYx applies high-throughput, systems-scale immune profiling and machine learning to support vaccine and antibody therapeutic discovery and development. Our platform integrates biophysical interaction assays, including Fc receptor and FcRn binding, with cell-based functional assays to comprehensively characterize Fc-mediated antibody activity and relate Fc effector functions to clinical and biological outcomes. Functional profiling capabilities include ADCC, ADCP, ADNKA, complement activation, and related antigen-dependent immune effector mechanisms. Applications span infectious disease, autoimmunity, neurodegeneration, and oncology, supporting discovery research, translational studies, and clinical development. By combining integrated systems serology, multivariate analytics and mechanistic immune profiling, SeromYx helps address the complexity and unpredictability of Fc effector biology in therapeutic antibody development as well as the limited availability of well-defined correlates of protection in vaccine development. Operating under a GCLP-based quality management system, SeromYx partners with clients to identify immune signatures associated with disease progression, protection, therapeutic response and disease resolution.